The RAS-RAF-MEK-ERK pathway (downstream of EGFR) could be activated by a low MED12 induced TGF-βR signaling pathway, suggesting that the EGFR Inhibitor would not be effective for advanced gastric cancer with a high-risk score. This evidence concerns the gene EGFR and gastric cancer.